ArticleAntimicrobial agents and chemotherapy2021
Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 44 citations in OpenAlex.
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Chelate-conjugated β-lactams resensitize metallo-β-lactamase IMP-1-producing gram-negative bacteria against carbapenem antibiotics.Microbiology spectrum · 2026Article
- Rising Incidence of New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Enterobacterales, 10 US Sites, 2018-2023.Open forum infectious diseases · 2026Article
- Increase in blaEmerging infectious diseases · 2026Article
- Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales.Microbiology spectrum · 2026Article
- Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre.Infection prevention in practice · 2026Article
- Cross-regional dynamics of antibiotic resistance (AR): Genomic evidence of transmission forEco-Environment & Health · 2026Article
- Detection of Carbapenem-Resistant Bacteria in Skilled Nursing Facility Wastewater.The Journal of infectious diseases · 2026Article
- The changing epidemiology and long-term outcomes of patients with CRE infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026Review
- Article
- Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023.Annals of internal medicine · 2025Article
- New Delhi metallo-β-lactamase-producing Acinetobacter baumannii in the USA from October, 2013, to March, 2022: a retrospective molecular epidemiological analysis.The Lancet. Microbe · 2025Article
- From detection to decision: how laboratory testing and reporting strategies can shape management of carbapenemase-producingASM case reports · 2025Article
- Molecular characterization of blaBMC infectious diseases · 2025Article
- Analysis of the microbiota of raw commercial feline diets to prioritize food safety investigations.Communications biology · 2025Article
- Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.Clinics in laboratory medicine · 2025Review
- Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenemase gene-positive (CP) Gram-negative bacilli are of significant clinical and public health concern. Their rapid detection and containment are critical to preventing their spread and additional infections they can cause. To this end, CDC developed the Antibiotic Resistance Laboratory Network (AR Lab Network), in which public health laboratories across all 50 states, several cities, and Puerto Rico characterize clinical isolates of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.